Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma.

Inclusion Criteria

Inclusion Criteria

Patients must have:

- HIV positive status and histologic confirmation of KS.

- CD4 count > 200 mm3 (required of one-half of patients).

- Minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions meeting
criteria for "indicator" lesions.

- Acceptable organ system function.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

Serious or intercurrent illness or infection that would interfere with the ability of the
patient to carry out the treatment program.

Prior Medication:

Excluded:

- Systemic therapy for KS within 30 days.

- Local or topical therapy for KS indicative lesions within 60 days.

- Systemic therapy with vitamin A in doses exceeding 15,000 IU per day or other
retinoid class drug.

Required:

Approved antiretroviral therapy.